Mallinckrodt plc v. Airgas Therapeutics LLC – INOmax® (Nitric Oxide)

Start
Case Name: Mallinckrodt plc v. Airgas Therapeutics LLC, Civ No. 22-1648-RGA, 2024 WL 1251260 (D. Del. Mar. 22, 2024) (Andrews, J.) – Drug Product and Patent(s)-in-Suit: INOmax® (nitric oxide); U.S. Patents Nos. 9,770,570 (“the ’570 patent”), 8,282,966 (“the ’966 patent”), 8,293,284 (“the ’284 patent”), 8,431,163 (“the ’163 patent”), 8,795,741 (“the ’741 patent”), 8,291,904 (“the ’904 patent”), 8,573,209 (“the ’209 patent”), 8,573,210 (“the ’210 patent), 8,776,794 (“the ’6794 patent”), 8,776,795…
By: Robins Kaplan LLP
Previous Story

HHS Extends the Antidiscrimination Provisions of the Affordable Care Act to Patient Care Decision Support Tools, Including Algorithms

Next Story

The State of Ransomware 2024